CA2759417C - Signature moleculaire pronostique des sarcomes et utilisations - Google Patents

Signature moleculaire pronostique des sarcomes et utilisations Download PDF

Info

Publication number
CA2759417C
CA2759417C CA2759417A CA2759417A CA2759417C CA 2759417 C CA2759417 C CA 2759417C CA 2759417 A CA2759417 A CA 2759417A CA 2759417 A CA2759417 A CA 2759417A CA 2759417 C CA2759417 C CA 2759417C
Authority
CA
Canada
Prior art keywords
tumor
seq
expression
polynucleotides
pool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2759417A
Other languages
English (en)
French (fr)
Other versions
CA2759417A1 (fr
Inventor
Frederic Chibon
Jean-Michel Coindre
Alain Aurias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Victor Segalen Bordeaux 2
Institute Curie
Institut Bergonie
Original Assignee
Universite Victor Segalen Bordeaux 2
Institute Curie
Institut Bergonie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Victor Segalen Bordeaux 2, Institute Curie, Institut Bergonie filed Critical Universite Victor Segalen Bordeaux 2
Publication of CA2759417A1 publication Critical patent/CA2759417A1/fr
Application granted granted Critical
Publication of CA2759417C publication Critical patent/CA2759417C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2759417A 2009-04-22 2010-04-21 Signature moleculaire pronostique des sarcomes et utilisations Expired - Fee Related CA2759417C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17149509P 2009-04-22 2009-04-22
US61/171,495 2009-04-22
FR09/01936 2009-04-22
FR0901936A FR2944805B1 (fr) 2009-04-22 2009-04-22 Signature moleculaire pronostique des sarcomes et utilisations
PCT/FR2010/000323 WO2010122243A1 (fr) 2009-04-22 2010-04-21 Signature moléculaire pronostique des sarcomes et utilisations

Publications (2)

Publication Number Publication Date
CA2759417A1 CA2759417A1 (fr) 2010-10-28
CA2759417C true CA2759417C (fr) 2018-05-08

Family

ID=42077215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759417A Expired - Fee Related CA2759417C (fr) 2009-04-22 2010-04-21 Signature moleculaire pronostique des sarcomes et utilisations

Country Status (6)

Country Link
US (1) US9708666B2 (enExample)
EP (1) EP2473622A1 (enExample)
JP (1) JP5865241B2 (enExample)
CA (1) CA2759417C (enExample)
FR (1) FR2944805B1 (enExample)
WO (1) WO2010122243A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064594A1 (en) 2015-03-06 2016-09-07 Université de Bordeaux Signature of clinical outcome in uterine smooth muscle tumor analysis, and method of diagnosis thereof
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
RU2625035C1 (ru) * 2016-09-06 2017-07-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования рецидивирования сарком мягких тканей
EP3530758A1 (en) 2018-02-23 2019-08-28 Université de Bordeaux Method for determining the in vitro presence of a target molecule in a biological sample, and its use for the in vitro analysis of cancers, in particular soft-tissue sarcomas and gastrointestinal stromal tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CA2568405A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
US8130007B2 (en) * 2006-10-16 2012-03-06 Formfactor, Inc. Probe card assembly with carbon nanotube probes having a spring mechanism therein

Also Published As

Publication number Publication date
JP5865241B2 (ja) 2016-02-17
CA2759417A1 (fr) 2010-10-28
EP2473622A1 (fr) 2012-07-11
US9708666B2 (en) 2017-07-18
WO2010122243A1 (fr) 2010-10-28
FR2944805B1 (fr) 2018-04-06
FR2944805A1 (fr) 2010-10-29
JP2012524537A (ja) 2012-10-18
US20130065772A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
Wach et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening
Bansal et al. Feasibility of microRNAs as biomarkers for Barrett's esophagus progression: a pilot cross-sectional, phase 2 biomarker study
CN103562409B (zh) 肺癌的生物标志物
JP2017532959A (ja) Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
WO2019157345A1 (en) Compositions and methods for characterizing bladder cancer
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
EP2791353A1 (fr) Procedes pour le diagnostic et le suivi therapeutique de dystrophies musculaires
CA2679208A1 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2016034715A2 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
JP2010537659A (ja) Ｅｒ−患者におけるガンの予後判定のための方法およびツール
AU2010264763B2 (en) Molecular markers in kidney cancer
US20150252425A1 (en) Gene expression profiling for the diagnosis of prostate cancer
CA2759417A1 (fr) Signature moleculaire pronostique des sarcomes et utilisations
WO2024091607A1 (en) Compositions and methods for treating renal cancer
WO2018160880A1 (en) Compositions and methods for detecting sessile serrated adenomas/polyps
EP3211096A1 (fr) Combinaison de miarns permettant la prediction de l'evolution clinique du cancer du rectum
EP2635705B1 (fr) Méthode de dépistage du cancer colorectal
WO2015127103A1 (en) Methods for treating hepatocellular carcinoma
JP7411979B2 (ja) 内部標準遺伝子
FR3158747A1 (fr) Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules
FR3158744A1 (fr) Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules
JP2026505350A (ja) 尿中の腎同種移植片拒絶反応遺伝子を同定するための方法およびそれらの測定を行うことの有用性
FR3155834A1 (fr) Biomarqueurs des chances de survie d’un patient atteint de lam
Karlsson Genomic characterization of non-small cell lung cancer-clinical and molecular implications
CN111979314A (zh) Mbd4基因用于视网膜母细胞瘤预后及耐药性诊断的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150227

MKLA Lapsed

Effective date: 20210421